[The initial clinical experience of using Ovosorb antiprotease hemosorbent in the combined treatment of dermatoses].
The new antiprotease hemosorbent Ovosorb was tested during the performance of blood perfusion (BP) used as part of multimodality treatment of 11 patients. Of these, 2 presented with disseminated psoriasis, 3 with arthropathic psoriasis, 1 with psoriatic erythrodermia, 4 with atopic dermatitis, and 1 with recurrent urticaria. BP with the use of the hemosorbent Ovosorb produced the highest effect in patients with atopic dermatitis, psoriatic erythrodermia and recurrent urticaria; BP with Ovosorb was less effective in disseminated psoriasis. The clinical effect was lacking in patients with arthropathic psoriasis. Ovosorb possesses remarkable detoxifying properties, good blood compatibility; it does not provoke any complications in patients with different forms of psoriasis, atopic dermatitis, and urticaria.
Mashkov
O A
OA
Mazur
L I
LI
Popov
A V
AV
Sorokin
B A
BA
Prokhorov
Iu S
IuS
D000180:Acrylic Resins / Q000627:therapeutic use*; D000328:Adult; D002908:Chronic Disease; D003131:Combined Modality Therapy; D005260:Female; D006464:Hemoperfusion / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010059:Ovomucin / Q000627:therapeutic use*; D011480:Protease Inhibitors / Q000627:therapeutic use*; D012871:Skin Diseases / Q000628:therapy*; D000099166:Polyacrylamides
D000180:Acrylic Resins; D010059:Ovomucin; D011480:Protease Inhibitors; D000099166:Polyacrylamides
Pervyĭ klinicheskiĭ opyt primeneniia antiproteaznogo gemosorbenta "Ovosorb" v kompleksnom lechenii nekotorykh dermatozov.